Yang, Sheng-Hsiang <br/><br/>
Rituximab induction therapy, survival benefits, and the increasing selection of radiotherapy as the postinduction treatment in patients with primary mediastinal large B-cell lymphoma.  [electronic resource] 

 -  Journal of the Chinese Medical Association : JCMA  Jul 2015 
 - 400-7 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1728-7731 
<br/><br/><label>Standard No.: </label>10.1016/j.jcma.2015.02.005  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adolescent<br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Antineoplastic Agents--therapeutic use<br/>Combined Modality Therapy<br/>Female<br/>Fluorodeoxyglucose F18<br/>Humans<br/>Induction Chemotherapy<br/>Lymphoma, Large B-Cell, Diffuse--mortality<br/>Male<br/>Mediastinal Neoplasms--mortality<br/>Middle Aged<br/>Positron-Emission Tomography<br/>Rituximab--therapeutic use